QuidelOrtho Corporation
QDELHealthcareNASDAQMedical Devices · Last scanned Jul 18, 2026
Scan Results
Daily timeframeQuidelOrtho Corporation provides diagnostic testing solutions. The $1.19B market capitalization puts QDEL squarely in small-cap range for its industry. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Market Cap
$1.19B
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
7.07
EPS (TTM)
$-17.85
EPS (Fwd)
$2.46
ROE
-50.0%
ROA
0.5%
Cash
$140.4M
Total Debt
$2.87B
Free CF
$208.6M
52W Change
-31.7%
Annual Financials
Cash vs Debt
QuidelOrtho Corporation carries $2.87B in total debt against $140.4M in cash reserves — debt is roughly 20.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $208.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -50.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $3.27B (2022) to $2.73B (2025), a 16% decline worth watching.
With a beta below 0.7, QuidelOrtho Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence QuidelOrtho Corporation's trajectory.